210 related articles for article (PubMed ID: 6689036)
1. [Myocardial infarct in a patient with Hodgkin's disease treated with cyclic polychemotherapy].
Matusewicz W; Drzewoski J; Robak T; Krykowski E
Kardiol Pol; 1983; 26(7):591-4. PubMed ID: 6689036
[No Abstract] [Full Text] [Related]
2. Immunoblastic lymphoma following therapy for Hodgkin's disease. A case report.
Casini M; Pianezze G; Fabris P; Cemin S; Coser P
Haematologica; 1986; 71(1):50-2. PubMed ID: 3084357
[No Abstract] [Full Text] [Related]
3. [Acute myeloid leukemia after treatment of Hodgkin's disease].
Carneiro PC; Pereira ED; Mitteldorf CS; Martinez GA; Beitler B; Pozzi DH
Rev Hosp Clin Fac Med Sao Paulo; 1989; 44(2):87-90. PubMed ID: 2616992
[TBL] [Abstract][Full Text] [Related]
4. Hodgkin's disease, splenectomy and secondary leukemia.
Centurioni R; Brianzoni F; Leoni P; Danieli G
Haematologica; 1993; 78(4):258-9. PubMed ID: 8294062
[No Abstract] [Full Text] [Related]
5. Osteonecrosis of sternum and rib in a patient treated for Hodgkin's disease.
Blijham GH; Vermeulen A; Mendes de Leon DE
Cancer; 1985 Nov; 56(9):2292-4. PubMed ID: 3840407
[TBL] [Abstract][Full Text] [Related]
6. The role of MOPP chemotherapy in early stage Hodgkin's disease.
Mauch P; Hellman S
Hematol Oncol; 1984; 2(1):66-9. PubMed ID: 6376318
[No Abstract] [Full Text] [Related]
7. Mediastinal Hodgkin's disease. Significance of mediastinal involvement in early stage Hodgkin's disease.
Mauch P; Hellman S
Hematol Oncol; 1984; 2(1):69-72. PubMed ID: 6547403
[No Abstract] [Full Text] [Related]
8. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study.
Brusamolino E; Anselmo AP; Klersy C; Santoro M; Orlandi E; Pagnucco G; Lunghi F; Maurizi-Enrici R; Baroni CD; Lazzarino M; Mandelli F; Bernasconi C
Haematologica; 1998 Sep; 83(9):812-23. PubMed ID: 9825578
[TBL] [Abstract][Full Text] [Related]
9. [Acute leukemia in patients treated for Hodgkin's disease].
Boccaccio P; Rosa F; Casciaro S; D'Elia P; Romagnoli M; Ghio R
Recenti Prog Med; 1988 Jan; 79(1):32-7. PubMed ID: 3375542
[No Abstract] [Full Text] [Related]
10. Hodgkin's disease and the risk of acute leukemia in successfully treated patients.
Valagussa P; Bonadonna G
Haematologica; 1998 Sep; 83(9):769-70. PubMed ID: 9825571
[No Abstract] [Full Text] [Related]
11. Cardiopulmonary response to exercise in patients with different degrees of lung toxicity after radio-chemotherapy for Hodgkin's disease.
Villani F; Busia A; Villani M; Laffranchi A; Viviani S; Bonfante V
Anticancer Res; 2009 Feb; 29(2):777-83. PubMed ID: 19331235
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxic chemotherapy-induced second primary neoplasms: clinical aspects.
Petru E; Schmähl D
Neoplasma; 1991; 38(2):147-55. PubMed ID: 2041574
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of Hodgkin's disease. Experience of the Hôpital Saint-Louis].
Boiron M; Teillet F; Weisgerber C; Dana M; Jacquillat C; Bernard J
Rev Prat; 1974 Oct; 24(45):3971-8. PubMed ID: 4445767
[No Abstract] [Full Text] [Related]
14. [Second tumor following Hodgkin's disease].
Schmitt K; Tulzer W
Padiatr Padol; 1984; 19(3):259-62. PubMed ID: 6548008
[TBL] [Abstract][Full Text] [Related]
15. High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.
Harrison CN; Gregory W; Hudson GV; Devereux S; Goldstone AH; Hancock B; Winfield D; MacMillan AK; Hoskin P; Newland AC; Milligan D; Linch DC
Br J Cancer; 1999 Oct; 81(3):476-83. PubMed ID: 10507773
[TBL] [Abstract][Full Text] [Related]
16. [MOPP therapy of Hodgkin's disease previously treated with MOPP].
Frau A; Montalar J
Med Clin (Barc); 1985 May; 84(19):801. PubMed ID: 3839875
[No Abstract] [Full Text] [Related]
17. [Chemotherapy of Hodgkin's disease].
Amiel JL; Mathé G
Rev Prat; 1974 Oct; 24(45):3957-60, 3963-4, 3967-8. PubMed ID: 4141118
[No Abstract] [Full Text] [Related]
18. CCNU, vinblastine, procarbazine and prednisone (CVPP) with extended-field radiotherapy in the treatment of early unfavorable Hodgkin's disease. A prospective study on behalf of the Gruppo Italiano per lo Studio dei Linfomi (GISL).
Gobbi PG; Pieresca C; Cavanna L; Corbella F; Vallisa D; Federico M; Formisano R; Carotenuto M; Merli F; Callea V; Angrilli F; Silingardi V
Haematologica; 1996; 81(6):503-12. PubMed ID: 9009437
[TBL] [Abstract][Full Text] [Related]
19. MOPP/ABV/CAD chemotherapy with and without recombinant human granulocyte-macrophage colony stimulating factor in untreated, unfavorable prognosis Hodgkin's disease.
Riccardi A; Gobbi P; Danova M; Giordano M; Pieresca C; Bertoloni D; Brugnatelli S; Ascari E
Haematologica; 1993; 78(1):44-8. PubMed ID: 7684012
[TBL] [Abstract][Full Text] [Related]
20. Two cycles of MOPP and definitive radiotherapy for stage IIIA and IIIB Hodgkin's disease.
Fuller LM; Hagemeister FB
Recent Results Cancer Res; 1989; 117():197-204. PubMed ID: 2602645
[No Abstract] [Full Text] [Related]
[Next] [New Search]
